Showing results (21-30 of 342) with videos related to
Sort By:
Pageof 35
Annals of Hematology|May 6, 2004
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemiaC H Pui, M V Relling, J T Sandlund, et al.Clinical Pharmacology and Therapeutics|September 1, 1991
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjectsM V Relling, J Cherrie, M J Schell, et al.Therapeutic Drug Monitoring|August 1, 1996
Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?M V RellingProceedings of the National Academy of Sciences of the United States of America|February 14, 1995
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferaseE Y Krynetski, J D Schuetz, A J Galpin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
Increased teniposide clearance with concomitant anticonvulsant therapyD K Baker, M V Relling, C H Pui, et al.The New England Journal of Medicine|February 19, 1998
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemiaW E Evans, M V Relling, J H Rodman, et al.Human Molecular Genetics|February 5, 1999
Polymorphism of the thiopurine S-methyltransferase gene in African-AmericansY Y Hon, M Y Fessing, C H Pui, et al.Clinical Pharmacology and Therapeutics|June 1, 1987
Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapyM V Relling, W R Crom, J A Pieper, et al.Leukemia|April 7, 1998
Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemiaM V Relling, Y Yanishevski, J Nemec, et al.Pageof 35